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Abstract FeyRIIIb is a glycosylphosphatidylinositol(GPI)-an-
chored, low-affinity IgG receptor, expressed exclusively on 
human neutrophils. Upon activation or apoptosis of neutrophils, 
FeyRIIIb is shed from the cell surface, but the enzyme(s) 
responsible for this process is (are) still unknown. Recently, 
metalloproteases have been suggested to mediate the shedding of 
cell surface proteins such as L-selectin and TNF-oc. Using 
hydroxamic acid-based inhibitors of this class of proteases (BB-
3103, Ro31-9790), we have observed a clear inhibitory effect on 
FeyRIIIb shedding after PMA stimulation of neutrophils or 
induction of apoptosis. These inhibitors did not affect PMA-
induced degranulation or superoxide generation. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
H u m a n neutrophils express two receptors for IgG: FcyRIIa 
(CD32) and Fcyll lb (CD16). FcyRIIa is a t ransmembrane 
protein, whereas FeyRIIIb is linked to the membrane via a 
glycosylphosphatidylinositol(GPI)-anchor [1]. Upon activa-
tion of neutrophils [2] or during apoptosis [3,4], FeyRIIIb is 
shed from the cell surface by proteolytic cleavage, but the 
enzyme(s) responsible for this process is (are) still unknown. 
Earlier studies indicated that the release of FeyRIIIb could be 
inhibited by protease inhibitors of serine proteases and metal-
loproteases [5,6]. Likewise, several other membrane molecules, 
such as L-selectin and T N F - a are released by proteolytic 
events from the leukocyte surface upon activation (see [7] 
for review). 
Soluble FcyRIII (sFcyRIII) in vivo is found in saliva, syno-
vial and seminal fluid, serum and plasma [8,9]. Also FcyRIIIa-
bearing cells, such as macrophages and N K cells, release this 
receptor by a proteolytic event. Plasma sFcyRIII, however, is 
mainly derived from neutrophils (Fcylllb) and is related to 
the production of neutrophils by the bone marrow [10-12]. 
The biological role of sFcyRIIIb is still unclear. Soluble 
Fcylll is still able to bind IgG, as shown by precipitates 
from plasma [5]. Studies with recombinant sFcyRIIIb showed 
binding to a subpopulation of B cells, T cells and monocytes 
[13], and inhibitory effects on B cell proliferation and IgG/ 
IgM production. Studies with purified sFcyRIIIb from serum 
have demonstrated cell activation through interaction with 
complement receptors (CR3 and CR4) [14]. These studies in-
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dicate that sFcyRIIIb plays an important role in Fc-dependent 
immune responses. 
Recently, a new class of compounds has been developed to 
inhibit matrix metalloproteases (MMP), hydroxamic acid-
based inhibitors, which also block other zinc-dependent pro-
teases such as mammalian adamalysins (ADAMs) . Shedding 
of a range of cell surface molecules, such as L-selectin, T N F - a , 
Fas ligand, I1-6R and T N F R ' s , is blocked by these com-
pounds[7]. 
In the present study we investigated by means of hydroxa-
mic acid-based inhibitors the possible involvement of metal-
loproteases in the shedding process of FeyRIIIb. 
2. Materials and methods 
2.1. Materials 
PMA and cytochalasin B were obtained from Sigma Chemical Co., 
St. Louis, MO, USA. Ro31-9790 was a kind gift from Roche Discov-
ery, Welwyn Garden City, UK and BB-3103 was a kind gift of British 
Biotechnology Pharmaceuticals, Oxford, UK. The following monoclo-
nals were obtained from our own institute: CLB-Fcgranl (FcyRIII), 
fluoresceine-isothiocyanate (FITC)-labeled CLB-Fcgranl, B13.9 
(CD66b) and irrelevant murine control IgGl. Leu-8 (CD62-L) was 
obtained from Becton and Dickinson, San Jose, CA, USA. (FITC)-
labeled Annexin V was a kind gift of Dr Reutelingsperger, Biochem-
istry Department, University of Limburg, Maastricht, The Nether-
lands. The inhibitory MoAb REGA-3G12 against human neutrophil 
gelatinase B (MMP-9)[15] was a kind gift of Dr. Liesbet Paemen, 
Laboratory of Molecular Immunology, Rega Institute for Medical 
Research, Leuven, Belgium. 
2.2. Isolation of neutrophils 
Peripheral blood was obtained from healthy volunteers. Granulo-
cytes were purified from the buffy coats of 500 ml of blood antico-
agulated with 0.4% (w/v) trisodium citrate, as described before [16]. In 
short, mononuclear cells and platelets were removed by density cen-
trifugation over isotonic Percoll with a specific gravity of 1.076 g/ml. 
Erythrocytes were removed by a 10-min treatment with ice-cold lysis 
buffer (155 mM NH4C1, 10 mM KHCO3 and 0.1 mM EDTA). The 
remaining granulocytes were washed twice in phosphate-buffered sal-
ine (PBS) and were resuspended in incubation medium [132 mM 
NaCl, 6 mM KC1, 1 mM CaCl2, 1 mM MgSO,, 1.2 mM NaHPO,, 
20 mM HEPES, 5.5 mM glucose and 0.5% (w/v) human serum albu-
min (pH 7.4)] at a concentration of 107 cells/ml. The purity and 
viability of the neutrophils was over 95%. 
2.3. Preparation of cytoplasts 
Enucleated neutrophils were prepared as described before [17]. In 
short, neutrophils were suspended in 12.5% (w/v) Ficoll solution with 
20 uM cytochalasin B. This cell suspension (approximately 108/ml) 
was preincubated for 5 min at 37°C. The suspension (10 ml) was 
then layered on a prewarmed (2 h at 37°C), discontinuous density 
gradient (10 ml of 16% Ficoll on top of 10 ml of 25% Ficoll). Cyto-
chalasin B (20 uM) was present throughout the gradient. Polycarbon-
ate centrifuge tubes (2.5X8.9 cm; Beckman Instruments Inc., Palo 
Alto, CA, USA) were used. After loading of the cells, the gradients 
were centrifuged for 30 min at 81 000 Xg and 33°C in an ultracentri-
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fuge (Kontron Electronic, Inc., Ultracentrifuge TGA 50, Zurich, Swit-
zerland), in a SW27 swing-out rotor (Beckman Instruments, Inc.) 
prewarmed for 4 h at 37°C. Cytoplasts were harvested from the 
12.5%/16% interface and were washed twice with incubation medium. 
2.4. Cell activation 
Neutrophils (107/ml) or cytoplasts (4xl07/ml) in incubation me-
dium were incubated in a shaking waterbath for 10 min at 37°C 
with the amount of Ro-31-9790 or BB-3103 indicated in the figures. 
The cells were subsequently activated with PMA (100 ng/ml) for 10 
min at 37°C. Cell-free supernatants were collected and cell pellets were 
fixed in ice-cold fixation buffer [5PBS containing bovine serum albu-
min (0.3% w/v) and paraformaldehyde (1% w/v)] for 10 min on ice. 
2.5. Flow cytometry 
Expression of FcyRIIIb, L-selectin and CD66b of the neutrophils or 
cytoplasts were determined by FACScan analysis. Fixed neutrophils 
or cytoplasts were washed once and were then incubated with MoAb 
for 45 min at 4°C in PBS containing bovine serum albumin (0.3% w/ 
v). The cells were subsequently stained with fluoresceine-isothiocya-
nate (FITC)-labeled goat-anti-mouse-Ig for 30 min at RT. After wash-
ing, the cells were resuspended in PBS containing bovine serum albu-
min (0.3%) w/v) and fluorescence was measured (FACScan, Becton 
and Dickinson, San Jose, CA, USA). 
2.6. Measurement of soluble FcyRIIIb in cell supernatants 
Soluble FcyRIIIb in neutrophil supernatant samples was measured 
by ELISA as described by Koene et al. [18]. In short, 96-well ELISA 
plates were coated with an Fcylllb catching MoAb CLB-Fcgranl and 
detection of sFcyRIIIb in the samples was performed with a biotin-
labeled, polyclonal rabbit-anti-human-FcyRIIIb antibody. After addi-
tion of streptavidin poly-horse-radish-peroxidase and substrate buffer, 
the color reaction was allowed to proceed for about 15 min after 
which the absorbance at 450 nm was measured in a Titertek multiscan 
ELISA reader (Flow Laboratory, Rockville, MD, USA). The concen-
tration of sFcylllb in each sample was calculated from a standard 
curve obtained by serial dilutions of human plasma containing 5 nM 
sFcylllb [5]. 
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Fig. 1. Inhibition of PMA-induced FcyRIIIb shedding by hydroxa-
mic acid-based inhibitors measured by ELISA. Human neutrophils 
(107/ml) were preincubated with different concentrations of BB-3103 
(•) or Ro31-9790 ( A ) for 10 min. After 10 min of PMA activation 
supernatant was collected and soluble FcyRIIIb was measured by 
ELISA. The concentration of sFcyRIII in the absence of inhibitors 
was taken as 100%>. This concentration amounted to 0.87 ±0.25 
(n - 5) pmol/ml. The results shown represent the mean of percentage 
soluble Fcylllb ± S.D. of three independent experiments. 
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Fig. 2. (A) Flow cytometry analysis of FcyRIIIb expression and An-
nexin V binding during apoptosis in presence of hydroxamic acid-
based inhibitors. Human neutrophils (107/ml) were incubated for 24 
h in the presence of DMSO (0.3%) as control (o), with BB-3103 
(100 uM, • ) or with Ro31-9790 (100 uM, A ) . At various times of 
incubation, cells were analyzed for FcyRIIIb expression (solid lines) 
and Annexin V binding (dashed lines). The results represent the 
mean of three independent experiments. (B) Inhibition of FcyRIIIb 
shedding by hydroxamic acid-based inhibitors during apoptosis as 
measured by ELISA. Human neutrophils (107/ml) were incubated 
for 24 h in the presence of DMSO (0.3%>) as control (o), with BB-
3103 (100 uM, • ) or with Ro31-9790 (100 uM, A ) . Soluble FcyRIII 
levels in cell-free supernatants at different times of incubation are 
shown. The concentration of sFcyRIII in supernatants after 24 h in 
the absence of inhibitors was taken as 100%>. This concentration 
amounted to 0.62 ±0.11 pmol/ml (« = 3). The results represent the 
mean of three independent experiments. 
2.7. Apoptosis 
Neutrophils (107/ml) in medium (Iscove's with 10%> (v/v) fetal calf 
serum) were cultured for 24 h at 37°C in 96-well plates in the presence 
of 100 uM BB-3103 or Ro31-9790. At various times, cell samples were 
taken. Cell-free supernatant was collected for measurement by ELISA 
of sFcylllb content. The cell pellets were washed and resuspended in 
ice-cold PBS containing bovine serum albumin (0.3%> w/v) and were 
stained with CD16-FITC for 30 min at 4°C. After washing, the cells 
were resuspended in ice-cold PBS containing bovine serum albumin 
(0.3% w/v), and the fluorescence was measured (FACScan, Becton 
and Dickinson, San Jose, CA, USA). For Annexin V binding, incu-
bation with FITC-labeled Annexin V and washing was performed in 
ice-cold incubation buffer [4]. 
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Fig. 3. Inhibition of PMA-induced FcyRIIIb shedding from cytoplasts by BB-3103. Cytoplasts (4xl07/ml) were preincubated with BB-3103 
(100 uM) for 10 min. After 10 min of PMA activation, the cytoplasts were fixed and analysed for FcyRIIIb expression by flow cytometry. De-
picted in the figure are: unstimulated cytoplasts (solid line), PMA-treated cytoplasts (broken line) and BB-3103/PMA-treated cytoplasts (dotted 
line). 
3. Results 
After PMA activation, neutrophil FcyRIIIb expression 
measured by flow cytometry was approximately 30% of the 
unstimulated control. In preliminary experiments, the hy-
droxamic acid-based inhibitors Ro31-9790 and BB-3103 in-
hibited this decrease in FcyRIIIb expression for about 50% 
(results not shown). The expression measured in this way is 
the net result of shedding from the surface and upregulation 
from secretory vesicles containing FcyRIIIb [11,19]. The ex-
tent of inhibition of FcyRIIIb shedding can be more reliably 
estimated by measuring soluble FcyRIIIb in the neutrophil 
supernatants. An inhibitory effect up to 70% on FcyRIII shed-
ding was measured with IC50's of approximately 0.1 uM for 
BB-3103 and 0.2 uM for Ro31-9790 (Fig. 1). Previous experi-
ments with serine- and metalloprotease inhibitors such as 
DFP, PMSF, EDTA and 1,10-phenanthroline in our group 
and others [5,6] already indicated that serine- and metallopro-
teases are probably involved in the shedding process of 
FcyRIIIb. However, in our hands these compounds inhibit 
not only the shedding process but also other processes, such 
as the fusion of granules with the cell surface and the oxida-
tive burst. The presence of hydroxamic acid-based inhibitors 
did not result in such inhibition. For instance, the PMA-up-
regulated expression of CD66b [20] was not affected: after 
FACS analysis values of 928 ± 429 (Mean Fluorescence Inten-
sity) for controls and 922 ±311 (n-3) in the presence of 10 
uM BB-3103, were found. Superoxide generation under these 
conditions amounted to in 7.8 ±0.5 nmol O2~/min/10
6 cells 
(mean±S.E.M. of 4 experiments) for the controls, 8.5 ±0.7 
(10 uM BB-3103) and 7.2 ±0.7 (10 uM Ro31-9790). 
Also during apoptosis, FcyRIIIb shedding was inhibited by 
the hydroxamic acid-based inhibitors (Fig. 2). Apoptosis it-
self, as measured by Annexin V binding [4], was not affected 
by these inhibitors. These results indicate that a similar pro-
teolytic enzyme is active during PMA activation and during 
apoptosis in cleaving the FcyRIIIb molecule from the surface 
of the human neutrophil. 
Human neutrophils contain two matrix metalloproteases in 
their specific granules, collagenase (MMP-8) and gelatinase B 
(MMP-9). To investigate their involvement in the FcyRIIIb 
shedding process, two experimental approaches were used. 
First, cytoplasts, which are enucleated neutrophils devoid of 
granules [17], were prepared. Cytoplasts retain functional re-
sponses such as respiratory burst, phagocytosis and shedding 
of FcyRIIIb [5,17]. In the presence of the hydroxamic based 
inhibitor BB-3103 (100 uM), no downregulation of FcyRIIIb 
was observed after PMA activation (Fig. 3). Similar results 
were obtained with Ro31-9790 (results not shown). This in-
dicates that the target protease for these inhibitors is still 
present in neutrophil cytoplasts and thus may be membrane 
bound. However, secretion of collagenase and gelatinase B 
and rebinding of these enzymes to the cell surface during 
cytoplast preparation cannot be excluded. We therefore used 
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Fig. 4. Inhibition of PMA-induced L-selectin shedding by hydroxa-
mic acid-based inhibitors. Human neutrophils (107/ml) were preincu-
bated with different concentrations of BB-3103 (•) or Ro31-9790 
( A ) for 10 min. After 10 min of PMA activation, the cells were 
fixed and analyzed for L-selectin expression. The results shown rep-
resent the mean ± S.D. of three independent experiments. 
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an inhibitory MoAb against human neutrophil gelatinase B 
[15] up to 50 ug/ml, and found no inhibitory effect on 
FcyRIIIb shedding as measured by FACS analysis: Mean 
Fluorescence Intensities amounting to 1684 ±202 (control) 
and 1733±165 (REGA-3G12) n-3, were observed. Gelatin-
ase B is therefore unlikely to be the shedding protease of 
FcyRIIIb, as discussed before [6]. 
Other membrane-bound molecules that can be shed after 
stimulation from human neutrophils are sialophorin (CD43), 
CD44, and L-selectin (CD62-L) [6,7]. Previous studies with 
leukocytes have shown that L-selectin shedding can be blocked 
by hydroxamic acid-based inhibitors [21-24]. In the present 
study, we have determined the sensitivity of the downregula-
tion of L-selectin for these inhibitors under the same experi-
mental conditions as those used for FcyRIIIb shedding (Fig. 
1). It appears that the IC5o of these inhibitors for FcyRIIIb 
downregulation is significantly lower than for L-selectin down-
regulation (Fig. 4). For the latter experiment ICso's of approx-
imately 3 |J.M were found, which is in good agreement with 
data published by Airport et al. [25]. An explanation could be 
that shedding of L-selectin requires another enzymatic process 
than FcyRIIIb shedding. Another observation that supports 
this explanation is the kinetics of downregulation of both 
molecules: shedding of L-selectin is much faster after PMA 
activation than FcyRIIIb shedding (results not shown). 
4. Discussion 
In the present study the involvement of a metalloprotease in 
the shedding of human neutrophil FcyRIIIb was investigated. 
A clear inhibitory effect was observed with hydroxamic acid-
based inhibitors. The presence of the inhibitors is required 
throughout the experiments (results not shown), which sug-
gests that the metalloprotease(s) responsible for FcyRIIIb 
shedding is upregulated from granules and/or activated at 
the cell surface. Involvement in the shedding process of 
known matrix metalloproteases from the granules of the neu-
trophil, collagenase and gelatinase B, is unlikely on the basis 
of our cytoplast experiments. Also secretion and rebinding of 
gelatinase B, after which cleavage could occur, is very un-
likely, because inhibition of this enzyme had no effect. Be-
cause FcyRIIIb is a GPI-anchored molecule, also phospholip-
ases could be candidate for the shedding of FcyRIIIb. Earlier 
studies, however, have excluded this possibility [5]. A mem-
brane-bound protease is more likely to be involved in the 
cleavage of Fcylllb. 
Hydroxamic acid-based inhibitors such as Ro31-9790 and 
BB-3103 have originally been developed to inhibit matrix met-
alloproteases. Ro31-9790 is known to be a potent inhibitor of 
fibroblast collagenase [22], whereas BB-3103, a water-soluble 
analogue of batimastat, shows inhibitory activity against both 
fibroblast collagenase and stromelysin 1 [26]. A possible target 
for these inhibitors could be a member of the family of mem-
brane-bound MMP's which has recently been cloned. Of 
these, expression of MT4-MMP has been shown on human 
neutrophils [27]. However, TACE (TNF-a Converting En-
zyme) is also inhibited by hydroxamic acid-based inhibitors 
but is not a matrix metalloprotease [28]. Recent cloning of 
TACE has shown that this enzyme is a metalloprotease dis-
integrin that cleaves TNF-a from cells [29,30]. This enzyme 
belongs to the family of ADAMs, which are thought to play 
an important role in cell-cell and cell-matrix interactions [31]. 
Also ADAM-10, another enzyme belonging to this family has 
shown to have TACE activity [32]. If this class of enzymes is 
responsible for the cleavage of all surface molecules, three 
possible candidates (other than MT4-MMP mentioned above) 
can be envisaged to cleave L-selectin and/or FcyRIIIb: the 
recently discovered TACE, CD 156 (ADAM-8) [33] and pos-
sibly ADAM-10. A comparison of kinetics of shedding and of 
sensitivity towards metalloprotease inhibitors suggests that 
FcyRIIIb shedding is probably mediated by other enzymes 
than those involved in L-selectin cleavage. Further studies 
are needed to identify the protease(s) responsible for the shed-
ding of FcyRIIIb. 
Acknowledgements: This study was supported by grant 900-512-092 
from the Netherlands Organization for Scientific Research (NWO). 
The authors wish to thank Dr. David Bradshaw (Roche Research 
Centre) and Dr. Alan Drummond (British Biotechnology Pharma-
ceuticals) for their kind gifts of inhibitors used in this study. 
References 
[e: 
[7 
[s: 
[? 
[io: 
in 
[12: 
[is: 
[14] 
[is: 
[is: 
[17 
[is: 
[19: 
[20: 
[21 
Anderson, C.L. and Looney, R J . (1986) Immunol. Today 9, 
264-266. 
Huizinga, T.W.J., van der Schoot, C.E., Jost, C , Klaassen, R., 
Kleijer, M., von dem Borne, A.E.K., Roos, D. and Tetteroo, 
P.A. (1988) Nature 333, 667-669. 
Dransfield, I., Buckle, A.M., Savill, J.S., McDowall, A., Haslett, 
C. and Hogg, N. (1994) J. Immunol. 153, 1254-1263. 
Homburg, C.H., de Haas, M., von dem Borne, A.E., Verhoeven, 
A.J., Reutelingsperger, C.P. and Roos, D. (1995) Blood 85, 532-
540. 
Huizinga, T.W., de Haas, M., Kleijer, M., Nuijens, J.H., Roos, 
D. and von dem Borne, A.E. (1990) J. Clin. Invest. 86, 416-
423. 
Bazil, V. and Strominger, J.L. (1994) J. Immunol. 152, 1314-
1322. 
Hooper, N.M., Karran, E.H. and Turner, A.J. (1997) Biochem. 
J. 321, 265-279. 
Sautes, C , Teillaud, C , Mazieres, N., Tartour, E., Bouchard, C , 
Galinha, A., Jourde, M., Spagnoli, R. and Fridman, W.H. (1992) 
Immunobiology 185, 207-221. 
Fleit, H.B., Kobasiuk, CD. , Daly, C , Furie, R., Levy, P.C. and 
Webster, R.O. (1992) Blood 79, 2721-2728. 
Huizinga, T.W., de Haas, M., van Oers, M.H., Kleijer, M., Vile, 
H., van der Wouw, P.A., Moulijn, A., van Weezel, H., Roos, D. 
and von dem Borne, A.E. (1994) Br. J. Haematol. 87, 459^463. 
de Haas, M., Kerst, J.M., van der Schoot, C.E., Calafat, J., 
Hack, C.E., Nuijens, J.H., Roos, D., van Oers, R.H. and von 
dem Borne, A.E. (1994) Blood 84, 3885-3894. 
Carr, R., Huizinga, T.W., Kleijer, M. and Davies, J.M. (1992) 
Pediatr. Res. 32, 505-508. 
Teillaud, C , Galon, J., Zilber, M.T., Mazieres, N., Spagnoli, R., 
Kurrle, R., Fridman, W.H. and Sautes, C. (1993) Blood 82, 
3081-3090. 
Galon, J., Gauchat, J.F., Mazieres, N., Spagnoli, R., Storkus, 
W., Lotze, M., Bonnefoy, J.Y., Fridman, W.H. and Sautes, C. 
(1996) J. Immunol. 157, 1184-1192. 
Paemen, L., Martens, E., Masure, S. and Opdenakker, G. (1995) 
Eur. J. Biochem. 234, 759-765. 
Roos, D. and De Boer, M. (1986) Methods Enzymol. 132, 225-
243. 
Roos, D., Voetman, A.A. and Meerhof, L.J. (1983) J. Cell Biol. 
97, 368-377. 
Koene, H.R., de Haas, M., Kleijer, M., Roos, D. and von dem 
Borne, A.E. (1996) Br. J. Haematol. 93, 235-241. 
Jost, C.R., Huizinga, T.W., de Goede, R., Fransen, J.A., Tette-
roo, P.A., Daha, M.R. and Ginsel, L.A. (1990) Blood 75, 144-
151. 
Niessen, H.W.M. and Verhoeven, A.J. (1992) Cell Sign. 4, 501-
509. 
Feehan, C , Darlak, K., Kahn, J., Walcheck, B., Spatola, A.F. 
and Kishimoto, T.K. (1996) J. Biol. Chem. 271, 7019-7024. 
[22] Preece, G., Murphy, G. and Ager, A. (1996) J. Biol. Chem. 271, 
11634-11640. 
[23] Bennett, T.A., Lynam, E.B., Sklar, L.A. and Rogelj, S. (1996) 
J. Immunol. 156, 3093-3097. 
[24] Arribas, J., Coodly, L., Vollmer, P., Kishimoto, T.K., Rose 
John, S. and Massague, J. (1996) J. Biol. Chem. 271, 11376-
11382. 
[25] Allport, J.R., Ding, H.T., Ager, A., Steeber, D.A., Tedder, T.F. 
and Luscinskas, F.W. (1997) J. Immunol. 158, 4365^-372. 
[26] Beckett, R.P., Davidson, A.H., Drummond, A.H., Huxley, P. 
and Whittaker, M. (1996) DDT 1, 16-26. 
[27] Puente, X.S., Pendas, A.M., Llano, E., Velasco, G. and Lopez-
Otin, C. (1996) Cancer Res. 56, 944-949. 
[28] Black, R.A., Durie, F.H., Otten Evans, C , Miller, R., Slack, 
J.L., Lynch, D.H., Castner, B., Mohler, K.M., Gerhart, M., 
Johnson, R.S., Itoh, Y., Okada, Y. and Nagase, H. (1996) Bio-
chem. Biophys. Res. Commun. 225, 400-405. 
[29] Black, R.A., Rauch, C.T., Kozlosky, C.J., Peschon, J.J., Slack, 
P.J. Middelhoven et al.lFEBS Letters 414 (1997) 14-18 
J.L., Wolfson, M.F., Castner, B.J., Stocking, K.L., Reddy, P., 
Srinivasan, S., Nelson, N., Boiani, N., Schooley, K.A., Gerhart, 
M., Davis, R., Fitzner, J.N., Johnson, R.S., Paxton, R.J., March, 
C.J. and Cerretti, D.P. (1997) Nature 385, 729-733. 
[30] Moss, M.L., Jin, S.L.C., Milla, M.E., Bickett, D.M., Bukhart, 
W., Carter, H.L., Chen, W.J., Clay, W.C., Didsbury, J.R., Hass-
ler, D., Hoffman, C.R., Kost, T.A., Lambert, M.H., Leesnitzer, 
M.A., McCauley, P., McGeehan, G., Mitchell, J., Moyer, M., 
Pahel, G., Rocque, W., Overton, L.K., Schoenen, F., Seaton, 
T., Su, J.L., Warner, J., Willard, D. and Becherer, J.D. (1997) 
Nature 385, 733-736. 
[31] Huovila, A.P.J., Almeida, E.A.C. and White, J.M. (1996) Curr. 
Opin. Cell Biol. 8, 692-699. 
[32] Lunn, C.A., Fan, X., Dalie, B., Miller, K., Zavodny, P.J., Nar-
ula, S.K. and Lundell, D. (1997) FEBS Lett. 400, 333-335. 
[33] Yoshiyama, K., Higuchi, Y., Kataoka, M., Matsuura, K. and 
Yamamoto, S. (1997) Genomics 41, 52-62. 
